Team
- Based on feedback from HP interactions with Bloomage Biotech, the team considered introducing an optimized trehalose metabolic pathway into the Antifreeze System to provide dual antifreeze capability, further enhancing the chassis's performance. Also worked on further optimizing and upgrading the Antifreeze Proteins.
Wet Lab
- Obtained 5 key endogenous trehalose synthesis genes (Key Gene 1-5) via PCR from yeast strain. Successfully constructed a trehalose plasmid containing these five target genes.
- Transformed the trehalose metabolic pathway plasmid into the EBY100 yeast. Conducted a series of antifreeze capability characterizations on the EBY100-pRS413-trehalose strain, confirming trehalose's potential to enhance the system's antifreeze performance.
- Discontinued construction of the domain-swapped fusion chassis due to poor antifreeze performance results from the previous characterization round.
- Characterized proteins obtained based on the inverse folding strategy (6A8K-IF, 4NU2-IF, 3WP9-IF) and the de novo synthesis strategy (De Novo).
- Guided by Dry Lab, began replacing the target sequence of AFP11 with smaller helical sequences from other proteins. Commercially synthesized and transformed constructs to create strains expressing a series of proteins, successfully building the NEW11-9, NEW11-10, NEW11-A, NEW11-B series chassis.
Dry Lab
- Used Molecular Dynamics simulation results for computational characterization.
- Designed smaller molecular weight short peptides based on enterprise feedback.
Human Practices (HP)
- Some team members attended the CCiC conference in Beijing, China. Presented the project to other teams from China. Received valuable suggestions from many iGEM team members and improved the project accordingly.
- Communicated and learned from iGEM Ambassador Patrick.
- Introduced iGEM and synthetic biology to high school students participating in the "Summit Plan" research camp and engaged in friendly discussions with them.